Skip to content

THE Effect of Tight Glycemic Control on Microvascular Complications in Type 2 Diabetes Mellitus

Effect of Tight Glycemic Control on Microvascular Complications in Type 2 Diabetes Mellitus: A Randomized Controlled Trial in an Egyptian Cohort

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07049601
Enrollment
80
Registered
2025-07-03
Start date
2022-05-11
Completion date
2023-10-30
Last updated
2025-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus

Keywords

tight glycemic control

Brief summary

The goal of this clinical trial is to learn the impact of tight versus less tight glycemic control on microvascular complications among Egyptian adults with uncontrolled T2DM. The main question it aims to answer is: Does tight glycemic control improve or worsens microvascular complications of diabetes compared to less tight glycemic control? Participants will: * Be divided to two groups according to their HbA1c group A tight glycemic control and less tight glycemic control. * Be followed for 6 months with clinical, laboratory, and fundoscopic evaluations performed at baseline and endpoint.

Detailed description

Background: Tight glycemic control is widely promoted in the management of type 2 diabetes mellitus (T2DM) to reduce microvascular complications, yet the extent and speed of HbA1c reduction may paradoxically exacerbate certain outcomes. Objective: To assess the impact of tight versus less tight glycemic control on microvascular complications among Egyptian adults with uncontrolled T2DM. Methods: In this randomized controlled trial, 80 patients with poorly controlled T2DM (HbA1c \>7.5%) were randomized into two groups: Group A (tight control, HbA1c \<7.0%) and Group B (less tight control, HbA1c \<7.5%). Participants were followed for 6 months with clinical, laboratory, and fundoscopic evaluations performed at baseline and endpoint.

Interventions

The effect of this intervention on HbA1c leading to either tight glycemic control HbA1c less than 7% or less tight glycemic control HbA1c less than 7.5%

OTHERAntidiabetic therapy, lifestyle modification

Individualized adjustments in antidiabetic therapy, lifestyle modification, and monthly clinical follow-up.

Sponsors

Ain Shams University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Both sexes. * Age 18-60years old. * Patients diagnosed with Diabetes Mellitus (Type 2) according to American Diabetes Association (ADA) guidelines. * Patients willing to participate after signing a written consent to be enrolled in the study after being explained to them in an interview. * Diabetic patients with mild and moderate non proliferative diabetic retinopathy

Exclusion criteria

* Patients with age above 60 or below 18 years old. * Patients with severe non proliferative diabetic retinopathy up to advanced proliferative diabetic retinopathy. * Patients diagnosed with type 1 DM. * Patients with malignant tumours. * Patients with end stage renal disease and end stage liver disease. * Patients with history of myocardial infarction. * Patients with recurrent attacks of hypoglycemia and hypoglycemia unawareness.

Design outcomes

Primary

MeasureTime frameDescription
Effect of Tight Glycemic Control on Microvascular Complications (Retinopathy, neuropathy and Nephropathy) in Type 2 Diabetes Mellitus in 80 patients divided into two groups according to their HbA1c18 months80 patients with poorly controlled T2DM (HbA1c \>7.5%) were randomized into two groups according to their HbA1c: Group A (tight control, HbA1c \<7.0%) and Group B (less tight control, HbA1c \<7.5%). Participants were followed for 6 months with clinical, laboratory and fundoscopic evaluations performed at baseline and endpoint.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026